CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry \[IHC\] 3+/2+/1+) advanced high-grade epithelial ovarian...
Phase 3
Milan, Italy and 179 other locations
followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian ...
Phase 3
Milano, Italy and 213 other locations
of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...
Phase 3
Milano, Italy and 126 other locations
in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian...
Phase 2
Milan, Italy and 52 other locations
the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian...
Phase 2
Milano, Italy and 46 other locations
Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....
Phase 3
Milan, Italy and 176 other locations
niraparib in combination with abemaciclib in patients with advanced ovarian cancer.Target population will be patients (woman, age \...
Phase 1, Phase 2
Milano, Italy
study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already ...
Phase 3
Milan, Italy and 176 other locations
(PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, expressing hig...
Phase 3
Milan, Italy and 124 other locations
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (I...
Phase 3
Milan, Italy and 105 other locations
Clinical trials
Research sites
Resources
Legal